tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Crescent Biopharma Ord Shs

CBIO
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
14.150USD
-0.220-1.53%
์ข…๊ฐ€ย 11-13 16:00๏ผˆET๏ผ‰
525.53M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM

Crescent Biopharma Ord Shs ์ •๋ณด ํšŒ์‚ฌ

Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Companyโ€™s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Companyโ€™s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.

Crescent Biopharma Ord Shs ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ - -
ํšŒ์‚ฌ ์ด๋ฆ„- -
์ƒ์žฅ์ผ- -
CEO- -
์ง์› ์ˆ˜- -
์œ ํ˜•- -
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒ- -
์ฃผ์†Œ- -
๋„์‹œ- -
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†Œ- -
๊ตญ๊ฐ€- -
์šฐํŽธ ๋ฒˆํ˜ธ- -
์ „ํ™”- -
์›น์‚ฌ์ดํŠธ- -
์ข…๋ชฉ ์ฝ”๋“œ - -
์ƒ์žฅ์ผ- -
CEO- -

Crescent Biopharma Ord Shs์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Director
Director
69.52K
--
Mr. Jonathan McNeill, M.D.
Mr. Jonathan McNeill, M.D.
President, Chief Operating Officer
President, Chief Operating Officer
10.03K
-45.59%
Dr. Ellie Eunkyung Im
Dr. Ellie Eunkyung Im
Chief Medical Officer
Chief Medical Officer
112.00
-1088.39%
Mr. Bruce Johnson
Mr. Bruce Johnson
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
Mr. Chinmaya Rath
Mr. Chinmaya Rath
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Independent Director
Independent Director
--
--
Mr. Joshua (Josh) Brumm
Mr. Joshua (Josh) Brumm
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Susan M. Moran, M.D.
Dr. Susan M. Moran, M.D.
Independent Director
Independent Director
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Director
Director
69.52K
--
Mr. Jonathan McNeill, M.D.
Mr. Jonathan McNeill, M.D.
President, Chief Operating Officer
President, Chief Operating Officer
10.03K
-45.59%
Dr. Ellie Eunkyung Im
Dr. Ellie Eunkyung Im
Chief Medical Officer
Chief Medical Officer
112.00
-1088.39%
Mr. Bruce Johnson
Mr. Bruce Johnson
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
Mr. Chinmaya Rath
Mr. Chinmaya Rath
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Independent Director
Independent Director
--
--

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Crescent Biopharma Ord Shs์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Crescent Biopharma Ord Shs์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Dr. Jonathan Violin, Ph.D.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ